Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030794 (pelvic pain)
 4,056 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

During the 18-month period from December 1, 1985 to May 31, 1987 Chlamydia trachomatis was the most-common sexually-transmitted agent to be identified at the Royal Women's Hospital, Melbourne. It was isolated from 4% of all specimens for which such culture was requested and was found five-times more frequently than was Neisseria gonorrhoeae. A review of the clinical presentation and the management of the 100 public patient for this period whose cervical specimens were found to give positive results for the presence of chlamydiae revealed that 77% of the women were less than 25 years of age, 78% of the women were single and 65% of the women were nulliparous. Thirty-five women were asymptomatic carriers of chlamydiae. Of the remaining 65 patients with symptoms, 46% experienced pelvic pain, 39% experienced a vaginal discharge and 26% experienced irregular bleeding. The importance of abnormal bleeding is emphasized. In patients who presented for therapeutic abortions, morbidity occurred in 19% of those who were carriers of Chl. trachomatis; accordingly, screening for chlamydiae as routine is recommended in such patients. Furthermore, because of the risk of pelvic inflammatory disease and its consequences, it is important not only to treat female patients in whom chlamydiae have been isolated, but also to treat and to follow-up their sexual partners simultaneously.
 ...
PMID:Chlamydia trachomatis infections--the Royal Women's Hospital experience. 271 99

A review was made of clinical and laboratory findings in 104 women who, during 1978 to 1981, were subjected to laparoscopy because of symptoms suggestive of acute salpingitis, and who harbored Chlamydia trachomatis but not Neisseria gonorrhoeae in the genital tract. The patients with acute salpingitis (N = 76) did not differ significantly from those with visually normal fallopian tubes (N = 28) in regard to age distribution, parity, contraceptive method used, proportion of women with urethritis symptoms, increased vaginal discharge, vomiting, diarrhea, elevated rectal temperature, elevated white blood cell count, and palpable pelvic masses. The acute salpingitis patients more often had irregular bleeding and an elevated erythrocyte sedimentation rate, whereas the patients without acute salpingitis more often had a short history of pelvic pain. The two groups overlapped considerably with respect to the number of symptoms and clinical signs of pelvic infection. The results emphasize the value of laparoscopy in the diagnosis or exclusion of a tubal infection in association with a chlamydial genital infection and pelvic pain, even if there are comparatively few additional symptoms of ascending infection.
 ...
PMID:Laparoscopy in women with chlamydial infection and pelvic pain: a comparison of patients with and without salpingitis. 621 34

The incidence of ovarian pregnancies is rare, a ratio of approximately .7 ovarian pregnancies to every 100 ectopic pregnancies. Since 1970, an increasing number of ovarian pregnancies associated with the use of IUDs are reported. A case report of a 34-year old woman, gravida 4, with an IUD in place for 18 months is presented. The patient complained of severe pelvic pain and moderate bleeding 5-6 weeks after her last normal menstrual period. Tissue, grossly ressembling placental tissue was passed, after which the pain stopped and the bleeding became minimal. On recurrence of pain and heavier bleeding, the patient underwent a dilatation and curretage and removal of the IUD, but the pain persisted. Ultrasound revealed a normal uterus and a left adnexal mass. Exploratory laparotomy to correct what was thought to be a hemorrhagic corpeus luteum cyst, resulted in a left oophorectomy. The pathology report showed an apparent gestational sac and a 10 mm embryo. In an analysis of 33 cases of ovarian pregnancy, another author noted the presence of vaginal bleeding, abdominal pain, uterine enlargement, and adnexal masses in a majority of cases on which the data were collected. Although the IUD has been shown to reduce the incidence of uterine implantation by 99.5% and tubal implantation by 95%, it does not reduce the incidence of ovarian pregnancy. Incidence of ovarian pregnancy among IUD users is thought to be 1 for every 7-9 ectopic pregnancies, in the general population, the incidence is 1 to every 150-200 ectopic pregnancies. This is probably due to the local enzyme or chemical action on the endometrial cavity and tubes. This apparent increase in ectopic pregnancies seems to be relevant only to the number of intrauterine pregnancies prevented by the IUD. Patients with IUDs, presenting with positive pregnancy tests, irregular bleeding and abdominal pain should be evaluated by ultrasound.
 ...
PMID:Ovarian pregnancy associated with a copper-7 intrauterine device: report of a case and review of the literature. 711 13

Chlamydia trachomatis was recovered from the fallopian tubes of ten women with acute salpingitis. The median age of the patients was 19 years. The duration of pelvic pain before consulting a physician ranged from three to 27 days (median, seven days). Half of the patients complained of irregular bleeding, and nine reported increased vaginal discharge. One patient had a rectal temperature of greater than 38 C, and one had an erythrocyte sedimentation rate of less than 15 mm/hr. At laparoscopy, mild inflammatory changes were seen in the tubes of three patients, five had moderately severe inflammation, and two had pelvic peritonitis. C. trachomatis could not be isolated from the cervix of two patients. Paired sera were available from eight patients, six of whom had a significant rise in titer of IgG antibodies to C. trachomatis. Two women had IgM antibodies. Two other women, who harbored Neisseria gonorrhoeae in the cervix, had antibodies to gonococcal pili; one had a significant decrease in titer. This latter patient was one of the patients with a stationary titer of antibodies to C trachomatis. One patient had a stationary titer of antibodies to Mycoplasma hominis. In general, chlamydial salpingitis seems to have relatively benign symptoms. Neither the failure to isolate C. trachomatis from the cervix nor a stationary titer of antibodies to the organism precludes a chlamydial etiology of acute salpingitis.
 ...
PMID:Acute salpingitis with Chlamydia trachomatis isolated from the fallopian tubes: clinical, cultural, and serologic findings. 725 92

The authors' previous research has demonstrated that treatment with 50-100 mg/day of mifepristone produces symptomatic improvement of endometriosis. The present study assessed the efficacy of a substantially reduced antiprogesterone dose. After a baseline cycle, 7 US women with pelvic pain caused by endometriosis were administered 5 mg of mifepristone daily for 6 months. Clinical responsiveness was evaluated in daily symptom inventories completed by study participants. Pelvic pain improved significantly within 1 month of treatment initiation in 6 of 7 patients. Cyclic bleeding ceased in all 7 patients, but 4 women complained of irregular bleeding that begin 3-5 months into treatment. Menstrual cyclicity returned 23-37 days after study completion. 2 women did not complete the study--1 because of continued pelvic pain and 1 because of heavy bleeding during the fifth cycle. Surgical staging through laparoscopy in the 5 remaining women failed to document a significant change in endometriosis. 1 woman had a slight increase in endometriosis score compared to baseline, 1 had no change, and the remaining 3 women showed decreases from 32-45%. Given the failure of the 5 mg dose to stabilize the endometrium and the high rate of uterine bleeding, a dose of 50 mg of mifepristone is recommended for future investigations.
 ...
PMID:Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). 966 95

Dienogest (DNG), a progestin of 19-nortestosterone derivative, has good oral bioavailability and is highly selective for progesterone receptors. Owing to its antiovulatory, antiproliferative activities in endometrial cells, and its inhibitory effects on the secretion of cytokines, DNG is expected to be an effective treatment for endometriosis. Progesterone receptor-binding affinity is higher for DNG than for progesterone. Several pilot studies demonstrated that after 24 weeks of DNG treatment, there was a significant decrease in terms of dysmenorrhea, premenstrual pain, dyspareunia and diffuse pelvic pain. Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding, which decreased with continued treatment and resolved either during treatment or after the end of treatment. The therapeutic effects of DNG 2 mg/day and norethisterone acetate 10 mg/day for endometriotic symptoms during a period of 24 weeks were almost similar. The only disadvantage of DNG seems to be the irregular bleeding. Good efficacy and tolerability of DNG in patients with endometriosis have been demonstrated in an open, randomized European clinical trial as compared with norethisterone acetate. In Japan, a Phase III, randomized, double-blind, multicenter, controlled trial was conducted to compare the efficacy and safety of DNG with intranasal buserelin acetate in patients with endometriosis. The study demonstrated that DNG is as effective as intranasal buserelin acetate in alleviating endometriosis symptoms, and causes less bone mineral density loss, resulting in the use on a commercial basis for endometriosis patients in Japan from 2008. This paper provides summarized data on this new promising drug for endometriosis.
 ...
PMID:Dienogest: a new therapeutic agent for the treatment of endometriosis. 2000 68

Tuberculosis (TB) infection poses substantial challenges for obstetricians and gynecologists globally, as gynecologic involvement may cause infertility, irregular bleeding, and pelvic pain. If TB-infected women are able to conceive, obstetric complications include intrauterine growth restriction and, more rarely, congenital transmission. Appropriate screening for high-risk populations is crucial for diagnosis and treatment of latent and active TB infection, which may prevent reproductive sequelae for individual patients and, eventually, contribute to complete eradication of the disease.
...
PMID:Tuberculosis and the obstetrician-gynecologist: a global perspective. 2482 6

In 2002, the U.S. Food and Drug Administration approved the Essure system for permanent birth control. Implantation with this device offers a minimally invasive option for permanent female contraception that is placed during a brief office visit. Unlike laparoscopic tubal sterilization, the Essure procedure requires no hospitalization or general anesthesia, resulting in minimal recovery time. After a decade of stability in the report of adverse effects, the U.S. Food and Drug Administration noted a sharp increase in patient-reported adverse events, including chronic pelvic pain, irregular bleeding, allergic reactions, and autoimmune-like reactions. In response to this increase in complaints, the U.S. Food and Drug Administration issued updated guidelines for patient education and counseling. This article discusses those updates, as well as implications for nurses who provide health care to women seeking permanent contraception.
 ...
PMID:Update on the Essure System for Permanent Birth Control. 2898 13